Follow
Sae-Won Han
Sae-Won Han
Professor of Internal Medicine, Seoul National University Hospital
Verified email at snu.ac.kr
Title
Cited by
Cited by
Year
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ...
Journal of clinical oncology 23 (11), 2493-2501, 2005
9852005
Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt …
SW Han, TY Kim, YK Jeon, PG Hwang, SA Im, KH Lee, JH Kim, DW Kim, ...
Clinical Cancer Research 12 (8), 2538-2544, 2006
3302006
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
B Keam, SA Im, KH Lee, SW Han, DY Oh, JH Kim, SH Lee, W Han, ...
Breast Cancer Research 13, 1-7, 2011
2952011
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ...
PloS one 12 (12), e0189848, 2017
2522017
Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index
Y Choi, DY Oh, TY Kim, KH Lee, SW Han, SA Im, TY Kim, YJ Bang
PloS one 10 (10), e0139749, 2015
2422015
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (IressaŽ, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer
SW Han, PG Hwang, DH Chung, DW Kim, SA Im, YT Kim, TY Kim, ...
International journal of cancer 113 (1), 109-115, 2005
2152005
Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic …
J Xu, TW Kim, L Shen, V Sriuranpong, H Pan, R Xu, W Guo, SW Han, ...
Journal of Clinical Oncology 36 (4), 350-358, 2018
2122018
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
SW Han, DY Oh, SA Im, SR Park, KW Lee, HS Song, NS Lee, KH Lee, ...
British Journal of Cancer 100 (2), 298-304, 2009
2082009
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
JC Bendell, TW Kim, BC Goh, J Wallin, DY Oh, SW Han, CB Lee, ...
Journal of Clinical Oncology 34 (15_suppl), 3502-3502, 2016
2022016
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
J Rhee, SW Han, DY Oh, JH Kim, SA Im, W Han, I Ae Park, DY Noh, ...
BMC cancer 8, 1-8, 2008
1982008
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple …
A Min, SA Im, DK Kim, SH Song, HJ Kim, KH Lee, TY Kim, SW Han, ...
Breast Cancer Research 17, 1-13, 2015
1742015
Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing
SW Han, HP Kim, JY Shin, EG Jeong, WC Lee, KH Lee, JK Won, TY Kim, ...
PloS one 8 (5), e64271, 2013
1742013
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
MG Fakih, S Kopetz, Y Kuboki, TW Kim, PN Munster, JC Krauss, ...
The Lancet Oncology 23 (1), 115-124, 2022
1692022
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
YK Yoon, HP Kim, SW Han, DY Oh, SA Im, YJ Bang, TY Kim
Molecular Carcinogenesis: Published in cooperation with the University of …, 2010
1592010
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive …
HG Yi, HJ Kim, YJ Kim, SW Han, DY Oh, SH Lee, DW Kim, SA Im, TY Kim, ...
Lung cancer 65 (1), 80-84, 2009
1552009
RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib
A Min, SA Im, YK Yoon, SH Song, HJ Nam, HS Hur, HP Kim, KH Lee, ...
Molecular cancer therapeutics 12 (6), 865-877, 2013
1492013
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for …
RH Xu, K Muro, S Morita, S Iwasa, SW Han, W Wang, M Kotaka, ...
The Lancet Oncology 19 (5), 660-671, 2018
1412018
High-purity capture and release of circulating exosomes using an exosome-specific dual-patterned immunofiltration (ExoDIF) device
YT Kang, YJ Kim, J Bu, YH Cho, SW Han, BI Moon
Nanoscale 9 (36), 13495-13505, 2017
1312017
Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors
DY Oh, SH Lee, SW Han, MJ Kim, TM Kim, TY Kim, DS Heo, M Yuasa, ...
Cancer research and treatment: official journal of Korean Cancer Association …, 2015
1312015
Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2
HP Kim, YK Yoon, JW Kim, SW Han, HS Hur, J Park, JH Lee, DY Oh, ...
PloS one 4 (6), e5933, 2009
1302009
The system can't perform the operation now. Try again later.
Articles 1–20